The authors of a Comment article note “although improvements in radiographic progression-free survival were previously reported from this trial and those data were sufficient for regulatory approval by several agencies, this confirmation of improved survival reaffirms the importance of secondary androgen biosynthesis inhibition (via CYP17 with abiraterone) in metastatic castration-resistant prostate cancer.” They add that in the past 5 years, seven phase 3 trials—including this study—with five different therapeutic modalities (including anti-androgens, chemotherapy, immunotherapy, and radiopharmaceuticals) have been shown to significantly extend survival in patients with metastatic castration-resistant prostate cancer, which is a remarkable series of advancements that have substantially altered how this cancer is treated.